vs
Side-by-side financial comparison of Biogen (BIIB) and State Street Corporation (STT). Click either name above to swap in a different company.
State Street Corporation is the larger business by last-quarter revenue ($3.7B vs $2.3B, roughly 1.6× Biogen). State Street Corporation runs the higher net margin — 20.4% vs -2.1%, a 22.5% gap on every dollar of revenue. On growth, State Street Corporation posted the faster year-over-year revenue change (7.5% vs -7.1%). State Street Corporation produced more free cash flow last quarter ($9.8B vs $468.0M). Over the past eight quarters, State Street Corporation's revenue compounded faster (8.1% CAGR vs -0.2%).
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
State Street Corporation is an American multinational financial services and bank holding company headquartered at One Congress Street in Boston. It is the second-oldest continuously operating U.S. bank, tracing its roots to Union Bank, chartered in 1792. As of the third quarter of 2025, State Street is one of the world's largest asset managers and custodians, with approximately US$5.4 trillion in assets under management and US$51.7 trillion under custody and administration.
BIIB vs STT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.3B | $3.7B |
| Net Profit | $-48.9M | $747.0M |
| Gross Margin | 78.3% | — |
| Operating Margin | -2.5% | 25.0% |
| Net Margin | -2.1% | 20.4% |
| Revenue YoY | -7.1% | 7.5% |
| Net Profit YoY | -118.3% | -4.6% |
| EPS (diluted) | $-0.35 | $2.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3B | $3.7B | ||
| Q3 25 | $2.5B | $3.5B | ||
| Q2 25 | $2.6B | $3.4B | ||
| Q1 25 | $2.4B | $3.3B | ||
| Q4 24 | $2.5B | $3.4B | ||
| Q3 24 | $2.5B | $3.3B | ||
| Q2 24 | $2.5B | $3.2B | ||
| Q1 24 | $2.3B | $3.1B |
| Q4 25 | $-48.9M | $747.0M | ||
| Q3 25 | $466.5M | $861.0M | ||
| Q2 25 | $634.8M | $693.0M | ||
| Q1 25 | $240.5M | $644.0M | ||
| Q4 24 | $266.7M | $783.0M | ||
| Q3 24 | $388.5M | $730.0M | ||
| Q2 24 | $583.6M | $711.0M | ||
| Q1 24 | $393.4M | $463.0M |
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
| Q4 25 | -2.5% | 25.0% | ||
| Q3 25 | 22.0% | 31.1% | ||
| Q2 25 | 28.1% | 25.8% | ||
| Q1 25 | 12.8% | 25.0% | ||
| Q4 24 | 11.9% | 28.1% | ||
| Q3 24 | 18.3% | 28.4% | ||
| Q2 24 | 28.3% | 28.6% | ||
| Q1 24 | 20.3% | 19.1% |
| Q4 25 | -2.1% | 20.4% | ||
| Q3 25 | 18.4% | 24.3% | ||
| Q2 25 | 24.0% | 20.1% | ||
| Q1 25 | 9.9% | 19.6% | ||
| Q4 24 | 10.9% | 22.9% | ||
| Q3 24 | 15.8% | 22.4% | ||
| Q2 24 | 23.7% | 22.3% | ||
| Q1 24 | 17.2% | 14.8% |
| Q4 25 | $-0.35 | $2.41 | ||
| Q3 25 | $3.17 | $2.78 | ||
| Q2 25 | $4.33 | $2.17 | ||
| Q1 25 | $1.64 | $2.04 | ||
| Q4 24 | $1.82 | $2.43 | ||
| Q3 24 | $2.66 | $2.26 | ||
| Q2 24 | $4.00 | $2.15 | ||
| Q1 24 | $2.70 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $6.3B | — |
| Stockholders' EquityBook value | $18.3B | $27.8B |
| Total Assets | $29.4B | $366.0B |
| Debt / EquityLower = less leverage | 0.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — | ||
| Q1 24 | $6.3B | — |
| Q4 25 | $18.3B | $27.8B | ||
| Q3 25 | $18.2B | $27.6B | ||
| Q2 25 | $17.6B | $27.3B | ||
| Q1 25 | $17.0B | $26.7B | ||
| Q4 24 | $16.7B | $25.3B | ||
| Q3 24 | $16.4B | $25.8B | ||
| Q2 24 | $15.9B | $24.8B | ||
| Q1 24 | $15.2B | $24.4B |
| Q4 25 | $29.4B | $366.0B | ||
| Q3 25 | $29.2B | $371.1B | ||
| Q2 25 | $28.3B | $376.7B | ||
| Q1 25 | $28.0B | $372.7B | ||
| Q4 24 | $28.0B | $353.2B | ||
| Q3 24 | $28.3B | $338.5B | ||
| Q2 24 | $26.8B | $325.6B | ||
| Q1 24 | $26.6B | $338.0B |
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — | ||
| Q1 24 | 0.41× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $511.9M | $10.0B |
| Free Cash FlowOCF − Capex | $468.0M | $9.8B |
| FCF MarginFCF / Revenue | 20.5% | 266.6% |
| Capex IntensityCapex / Revenue | 1.9% | 7.3% |
| Cash ConversionOCF / Net Profit | — | 13.44× |
| TTM Free Cash FlowTrailing 4 quarters | $2.1B | $10.8B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $511.9M | $10.0B | ||
| Q3 25 | $1.3B | $7.9B | ||
| Q2 25 | $160.9M | $-8.4B | ||
| Q1 25 | $259.3M | $2.4B | ||
| Q4 24 | $760.9M | $-7.4B | ||
| Q3 24 | $935.6M | $2.7B | ||
| Q2 24 | $625.8M | $-7.6B | ||
| Q1 24 | $553.2M | $-844.0M |
| Q4 25 | $468.0M | $9.8B | ||
| Q3 25 | $1.2B | $7.7B | ||
| Q2 25 | $134.3M | $-8.8B | ||
| Q1 25 | $222.2M | $2.2B | ||
| Q4 24 | $721.6M | $-7.7B | ||
| Q3 24 | $900.6M | $2.5B | ||
| Q2 24 | $592.3M | $-7.9B | ||
| Q1 24 | $507.3M | $-1.1B |
| Q4 25 | 20.5% | 266.6% | ||
| Q3 25 | 48.4% | 216.0% | ||
| Q2 25 | 5.1% | -254.1% | ||
| Q1 25 | 9.1% | 66.1% | ||
| Q4 24 | 29.4% | -225.1% | ||
| Q3 24 | 36.5% | 75.9% | ||
| Q2 24 | 24.0% | -246.2% | ||
| Q1 24 | 22.1% | -34.2% |
| Q4 25 | 1.9% | 7.3% | ||
| Q3 25 | 1.8% | 6.9% | ||
| Q2 25 | 1.0% | 9.3% | ||
| Q1 25 | 1.5% | 6.9% | ||
| Q4 24 | 1.6% | 7.3% | ||
| Q3 24 | 1.4% | 7.2% | ||
| Q2 24 | 1.4% | 6.7% | ||
| Q1 24 | 2.0% | 7.3% |
| Q4 25 | — | 13.44× | ||
| Q3 25 | 2.73× | 9.18× | ||
| Q2 25 | 0.25× | -12.18× | ||
| Q1 25 | 1.08× | 3.72× | ||
| Q4 24 | 2.85× | -9.49× | ||
| Q3 24 | 2.41× | 3.71× | ||
| Q2 24 | 1.07× | -10.75× | ||
| Q1 24 | 1.41× | -1.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
STT
| Other | $2.2B | 59% |
| Investment Management | $729.0M | 20% |
| Management Services | $662.0M | 18% |
| Other Fee Revenue | $56.0M | 2% |
| Securities Financing Services | $54.0M | 1% |
